ARCHIVES

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

Armand Hammer Panel chairman; DeVita Announces Greenwald Appointment; Adamson To Be DCCP Director

October 9, 1981

NHGRI Director Francis Collins To Step Down.

May 30, 2008

House-Senate Conference Agrees On $1 Billion For NCI, Increases For All NIH Organizations

August 3, 1979

Low Prevalence Of Tamoxifen Use For Cancer Prevention

February 26, 2010

Ontak Approved For Lymphoma

October 31, 2008

Lymphatic Mapping Techniques Can Outperform “Watch-and-Wait”

February 28, 2014